Gli-M Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which helps reduce blood glucose levels without causing significant hypoglycemia. The synergistic action of these two agents provides effective glycemic regulation in patients inadequately controlled by diet and exercise alone. Gli-M Tablet is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and physical activity. It is contraindicated in patients with severe renal or hepatic impairment, diabetic ketoacidosis, or hypersensitivity to either component. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Gli-M Tablet should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.